HDAC7 and central nervous system cancer: Our results align with a previously demonstrated better outcome for high-expressing patients of specific class IIA HDAC members, specifically in non-small cell lung carcinomas [58], HDAC7 in triple-negative breast cancers [59], and HDAC4/5 in gliomas [60].